Other epigentic modifiers TET2 and CREBBP (both 20%, 5/25) were also frequently affected in NMZL, closely followed by BRAF, EZH2, and TNFRSF14 (each 16%, 4/25). The gene discussed is BRAF; the disease is nodal marginal zone B-cell lymphoma.